Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B

Abstract

LINKED CONTENT This article is linked to Papatheodoridis et al papers. To view these articles, visit https://doi.org/10.1111/apt.17093 and https://doi.org/10.1111/apt.17146

Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer

“…6 A Recent study further demonstrated that the lipid profiles greatly increased in HBV patients switching from TDF to TAF, but not in patients switching from entecavir to TAF. 7 Meanwhile, the presence of metabolic traits, including gain of body weight, worsening of insulin resistance, and a trend towards increased atherosclerotic cardiovascular disease scores, may possibly predispose to cardiovascular diseases in TDF-switch patients. These results indicated that TDF and TAF may exert effects on metabolic risk factors other than lipid profiles.…”

Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic hepatitis B patients—author's reply

“…Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic hepatitis B patients-author's reply I would like to thank Drs. Tseng and Chen for their thoughtful editorial 1 commenting on our recent HERACLIS-TAF prospective cohort study, which assessed the changes of estimated glomerular filtration rate (eGFR) and other safety and efficacy parameters during 24-months of tenofovir alafenamide (TAF) in patients with chronic hepatitis B (CHB) treated in Greece. 2 I agree with their comments and approach, but I would like to clarify a few issues in an effort to explain some seemingly conflicting reports on changes of safety parameters during TAF therapy.…”

“…I would like to thank Drs. Tseng and Chen for their thoughtful editorial 1 commenting on our recent HERACLIS‐TAF prospective cohort study, which assessed the changes of estimated glomerular filtration rate (eGFR) and other safety and efficacy parameters during 24‐months of tenofovir alafenamide (TAF) in patients with chronic hepatitis B (CHB) treated in Greece 2 …”

Editorial: Tenofovir disoproxil fumarate more than an antiviral drug—Another piece of the puzzle. Authors' reply

“…Tenofovir disoproxil fumarate (TDF) has unique and well‐known lipid‐lowering effects in patients with CHB 5 . We demonstrated that the lipid‐lowering effects of TDF disappear, body weight increases and insulin resistance deteriorates shortly following a switch to tenofovir alafenamide (TAF), and that these effects are maintained through 48 weeks of TAF 6 . Furthermore, a trend towards an increase of ASCVD score following a switch from TDF to TAF is also observed.…”